Skip to main content

Table 3 The clinic-pathological parameters among patients with different treatment response and toxicity

From: Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Characteristic

Response to chemotherapy(N = 90)

Toxicity to chemotherapy(N = 211)

Response (N = 29)

Non-response (N = 61)

p

Toxicity (N = 102)

No toxicity (N = 109)

P

Age in years(mean ± SD)

0.539

  

0.195

  ≤ 45

4(13.8)

10(16.4)

 

17(16.7)

22(20.2)

 

 46–55

10(34.5)

27(44.3)

 

39(38.2)

29(26.6)

 

  > 55

15(51.7)

24(39.3)

 

46(45.1)

58(53.2)

 

Menstrual status

0.516

  

0.891

 Premenopausal

8(27.6)

21(34.4)

 

30(29.4)

33(30.3)

 

 Postmenopausal

21(72.4)

40(65.6)

 

72(70.6)

76(69.7)

 

T-status,n(%)

0.250

  

<0.001*

 T1

/

/

 

/

/

 

 T2

1(3.4)

5(8.2)

 

17(16.7)

74(67.9)

 

 T3

27(93.1)

56(91.8)

 

84(82.4)

32(29.4)

 

 T4

1(3.4)

0(0)

 

1(1.0)

3(2.8)

 

N-status,n(%)

0.209

  

0.168

 N0

7(24.1)

27(44.3)

 

38(37.3)

27(24.8)

 

 N1

13(44.8)

23(37.7)

 

40(39.2)

58(53.2)

 

 N2

6(20.7)

9(14.8)

 

18(17.6)

19(17.4)

 

 N3

3(10.3)

2(3.3)

 

6(5.9)

5(4.6)

 

Tumor grade

0.066

  

0.078

 Grade I

/

/

 

/

/

 

 Grade II

7(24.1)

27(44.3)

 

41(40.2)

57(52.3)

 

 Grade III

22(75.9)

34(55.7)

 

61(59.8)

52(47.7)

 

ER status

0.050

  

0.650

 Positive

24(82.8)

38(62.3)

 

72(70.6)

80(73.4)

 

 Negative

5(17.2)

23(37.7)

 

30(29.4)

29(26.6)

 

PR status

0.476

  

0.995

 Positive

24(82.8)

38(62.3)

 

59(57.8)

63(57.8)

 

 Negative

5(17.2)

23(37.7)

 

43(42.2)

46(42.2)

 

Her2 status

0.883

  

0.525

 Positive

10(34.5)

22(36.1)

 

35(34.3)

42(38.5)

 

 Negative

19(65.5)

39(63.9)

 

67(65.7)

67(61.5)

 

TNBC

0.618

  

0.428

 yes

2(6.9)

15(24.6)

 

16(15.7)

13(11.9)

 

 no

27(93.1)

46(75.4)

 

86(84.3)

96(88.1)

 

P63

0.967

  

0.281

 positive

1(3.4)

2(3.3)

 

3(2.9)

1(0.9)

 

 negative

28(96.6)

59(96.7)

    

Ki-67

0.324

17(16.7)

22(20.2)

0.195

  < 20%

7(24.1)

21(34.4)

 

39(38.2)

29(26.6)

 

  ≥ 20%

22(75.9)

40(65.6)

 

46(45.1)

58(53.2)

 
  1. T tumor stage, N nodes stage, TNBC triple negative breast cancer, Her 2 human epidermal growth factor receptor 2; * A P value < 0.05 was considered ststistically significant